Monoclonal antibodies are a class of therapeutic proteins designed to target specific antigens, thereby aiding the immune system in recognizing and neutralizing threats. However, during the manufacturing process, these antibodies may sometimes exhibit higher viscosity levels, which can impede their delivery, formulation, and overall efficacy. Elevated viscosity can lead to challenges in production, storage, and administration, ultimately affecting patient outcomes.
There are complications that can happen with elevated viscosity including:
Difficulties in Formulation: High viscosity can hinder the proper formulation of mAbs, affecting their solubility and stability in various formulations.
Injection Challenges: Viscosity can make it harder to inject the drug through injectables, impacting patient comfort and compliance.
Storage Concerns: Viscous solutions might experience problems during storage, leading to issues such as aggregation or precipitation.
With such potential formulation challenges and factors to consider, Comera Life Sciences is exploring the caffeine impact on viscosity of their mAbs. Research has shown that caffeine has the ability to interact with the molecular structure of monoclonal antibodies, leading to a reduction in their viscosity. This interaction is believed to influence the conformation and spatial arrangement of mAbs, mitigating the factors that contribute to high viscosity levels. As a result, the optimized antibodies exhibit improved flow properties, making them easier to formulate, store, and administer.
With such insight, it would be quite interesting to see how caffeine can be increasingly used as a tool in the world of mAbs. Interested in checking out potential data generated with collaboration with Comera Life Sciences?
Check out our latest application note where we collaborated with Comera Life Sciences on generating viscosity data with their mAbs.